Tag: ctu

The UNC IGHID Clinical Trials Unit (CTU) participated in the “Vision for Change: Empowering Communities in NC through Community Engagement” event on Saturday, August 30 at the Community Family Life & Recreation Center at Lyon Park in Durham. Our team (Miriam, Ann, and Tia) joined Alicia Diggs with UNC CFAR,...

Clinical Trials Day honors all that has been accomplished through clinical trials, as well as the people behind them. The UNC Global Clinical Trials Unit at the Institute for Global Health and Infectious Diseases (IGHID) facilitates high-quality research, with investigators and research coordinators working to address the challenging questions that need...

The Institute for Global Health and Infectious Disease’s Global Clinical Trials Unit attracts leading trials from national feeder networks to study treatment innovations that can advance health. A new HIV study with the ACTG will evaluate the safety, tolerability, and antiviral effect of a novel combination regimen that includes therapeutic...

Despite a decline in HIV incidence in women in the U.S., approximately 18% of new HIV diagnoses in 2021 were among women. Meanwhile, many cisgender women have not considered HIV PrEP (pre-exposure prophylaxis) as an option for themselves when it comes to HIV prevention. Historically, studies of interventions to prevent...

March is Long COVID Awareness Month, marking four years since COVID-19 was declared a pandemic. But while much of society has moved on from masking, quarantining, and isolating, there are many who are managing health problems long after having COVID-19.  Researchers at the Institute for Global Health and Infectious Diseases are participating in the NIH...

The UNC Institute for Global Health and Infectious Diseases is now enrolling participants in a fast-track trial of an oral COVID-19 treatment known as Bemnifosbuvir (BEM). Currently, Paxlovid is used for treating COVID-19. However, it is known to interact with common drugs that treat cholesterol, blood clots, and other conditions....

Antiretroviral therapies (ART) stop HIV replication in its tracks, allowing people with HIV to live relatively normal lives. However, despite these treatments, some HIV still lingers inside cells in a dormant state known as “latency.” If ART is discontinued, HIV will awaken from its dormant state, begin to replicate, and...

Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through...

Infectious disease research at the UNC Institute for Global Health and Infectious Diseases (IGHID) attracts unique people driven to make big change in the world. As HIV/AIDS turned 40 in 2021, the world was immersed in a different pandemic, one that brought reminders of the tremendous change science made possible...

In 2021, women and girls in sub-Saharan Africa accounted for three of five new HIV infections, and young women aged 15–24 years were three times as likely as young men in the same age group to be infected with HIV. Despite expanded access to oral PrEP, women are disproportionately affected...

UNC Has Launched the Largest COVID-19 Observational Study of its Kind in North Carolina The VISION study led by the UNC Institute for Global Health & Infectious Diseases is enrolling 7,500 COVID-positive individuals in North Carolina to answer critical questions about their health through online surveys. Approximately 750 participants will...